Sage Therapeutics Rejects Biogen’s Takeover Offer

Sage Therapeutics announced that its board of directors has unanimously rejected the proposal it received from Biogen on Jan. 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share, representing an equity value of about $469 million.

In addition, Sage announced that its board has initiated a process to explore strategic alternatives for the company. It intends to evaluate a broad range of opportunities to maximize value for shareholders, including but not limited to a potential strategic transaction, business combination or sale.

Sage stated that it has not set a timetable for the review process, nor has it made any decisions related to any potential strategic alternatives at this time. The company does not intend to disclose further developments on this strategic review process unless necessary.

While the company’s board conducts its review, Sage wants to remain focused on establishing Zurzuvae, which it co-developed with Biogen, as the standard of care for women with postpartum depression (PPD).

© sirtravelalot/Shutterstock
© sirtravelalot/Shutterstock

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.